Literature DB >> 22471865

The Framingham Brain Donation Program: neuropathology along the cognitive continuum.

Rhoda Au1, Sudha Seshadri, Kristen Knox, Alexa Beiser, Jayandra J Himali, Howard J Cabral, Sanford Auerbach, Robert C Green, Philip A Wolf, Ann C McKee.   

Abstract

The Framingham Heart Study has enrolled 3 generations of participants, the original cohort (gen 1) enrolled in 1948, the offspring cohort (gen 2) enrolled in 1971 and the third generation enrolled in 2002. Participants have been undergoing prospective surveillance for incident stroke and dementia and embedded within this cohort is the voluntary Framingham Brain Donation Program that was begun in 1997. Participants who register to become brain donors have had one or more brain MR and cognitive test batteries administered. In addition, they undergo neurological evaluation as indicated, record review and post-mortem next-of-kin interview to determine the presence, type and extent of antemortem, clinical neurological diagnoses and to assign a retrospective clinical dementia rating (CDR) Scale score. Between 1997 and 2009 there were 1806 deaths, 186 of which were among registered brain donors and of these 139 brains could be examined. 58% were deemed cognitively normal at death. We present results for 3 projects; the first was to examine the sensitivity and specificity of our clinical diagnosis against the gold standard of pathological AD in 59 persons who underwent detailed cognitive assessment in the two years prior to death; we observed a 77.3% sensitivity (2 persons with AD were diagnosed clinically as Lewy body dementia) and a 91.9% specificity. The second examined the correlation of regional Alzheimer-type pathology to cognitive status at death among 34 persons who were over the age of 75 and without any significant vascular or alternative neurodegenerative pathology and found that neurofibrillary tangle counts distinguished between persons who were controls, had mild cognitive impairment, mild or moderate dementia; tangles in dorsolateral frontal cortex best distinguished MCI and controls. The third project examined the extent and severity of vascular pathology, again in a larger sample of varying cognitive abilities and in a subsample of persons with either amnestic or nonamnestic MCI. We observed that an aggregate ischemic injury score was significantly higher in persons with a CDR score of 0.5 than in normal controls.

Entities:  

Mesh:

Year:  2012        PMID: 22471865      PMCID: PMC3622706          DOI: 10.2174/156720512801322609

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  70 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer's disease.

Authors:  Julie A Schneider
Journal:  J Am Geriatr Soc       Date:  2009-11       Impact factor: 5.562

3.  Microinfarct pathology, dementia, and cognitive systems.

Authors:  Zoe Arvanitakis; Sue E Leurgans; Lisa L Barnes; David A Bennett; Julie A Schneider
Journal:  Stroke       Date:  2011-01-06       Impact factor: 7.914

4.  Modulators of cytoskeletal reorganization in CA1 hippocampal neurons show increased expression in patients at mid-stage Alzheimer's disease.

Authors:  Patricia F Kao; David A Davis; Meredith G Banigan; Charles R Vanderburg; Sudha Seshadri; Ivana Delalle
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

5.  Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study.

Authors:  J P Vonsattel; R H Myers; E T Hedley-Whyte; A H Ropper; E D Bird; E P Richardson
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

Review 6.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  Neuritic pathology and dementia in Alzheimer's disease.

Authors:  A C McKee; K S Kosik; N W Kowall
Journal:  Ann Neurol       Date:  1991-08       Impact factor: 10.422

Review 8.  Epidemiological studies of the effect of stroke on incident dementia: a systematic review.

Authors:  George M Savva; Blossom C M Stephan
Journal:  Stroke       Date:  2009-11-12       Impact factor: 7.914

Review 9.  Role of vascular risk factors and vascular dysfunction in Alzheimer's disease.

Authors:  Dara L Dickstein; Jessica Walsh; Hannah Brautigam; Steven D Stockton; Samuel Gandy; Patrick R Hof
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

Review 10.  Neuropathology of Alzheimer's disease.

Authors:  Daniel P Perl
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb
View more
  31 in total

1.  Methionine Sulfoxide Reductase-B3 (MsrB3) Protein Associates with Synaptic Vesicles and its Expression Changes in the Hippocampi of Alzheimer's Disease Patients.

Authors:  Stephanie L Adams; Laurent Benayoun; Kathy Tilton; Olivia R Chavez; Jayandra J Himali; Jan Krzysztof Blusztajn; Sudha Seshadri; Ivana Delalle
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology.

Authors:  Katherine J Bangen; Jayandra J Himali; Alexa S Beiser; Daniel A Nation; David J Libon; Caroline S Fox; Sudha Seshadri; Philip A Wolf; Ann C McKee; Rhoda Au; Lisa Delano-Wood
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

3.  Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage.

Authors:  Sergi Martinez-Ramirez; Jose-Rafael Romero; Ashkan Shoamanesh; Ann C McKee; Ellis Van Etten; Octavio Pontes-Neto; Eric A Macklin; Alison Ayres; Eitan Auriel; Jayandra J Himali; Alexa S Beiser; Charles DeCarli; Thor D Stein; Victor E Alvarez; Matthew P Frosch; Jonathan Rosand; Steven M Greenberg; M Edip Gurol; Sudha Seshadri; Anand Viswanathan
Journal:  Alzheimers Dement       Date:  2015-06-13       Impact factor: 21.566

4.  Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.

Authors:  Stephanie L Adams; Laurent Benayoun; Kathy Tilton; Tiffany J Mellott; Sudha Seshadri; Jan Krzysztof Blusztajn; Ivana Delalle
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease.

Authors:  Katherine J Bangen; Daniel A Nation; Lisa Delano-Wood; Gali H Weissberger; Lawrence A Hansen; Douglas R Galasko; David P Salmon; Mark W Bondi
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

Review 6.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

7.  Association between neuropathology and brain volume in the Framingham Heart Study.

Authors:  Berneet Kaur; Jayandra J Himali; Sudha Seshadri; Alexa S Beiser; Rhoda Au; Ann C McKee; Sanford Auerbach; Philip A Wolf; Charles S DeCarli
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jul-Sep       Impact factor: 2.703

8.  Genetic Interaction with Plasma Lipids on Alzheimer's Disease in the Framingham Heart Study.

Authors:  Gina M Peloso; Alexa S Beiser; Anita L Destefano; Sudha Seshadri
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 9.  Impact of multiple pathologies on the threshold for clinically overt dementia.

Authors:  Alifiya Kapasi; Charles DeCarli; Julie A Schneider
Journal:  Acta Neuropathol       Date:  2017-05-09       Impact factor: 17.088

Review 10.  The neuropathology of sport.

Authors:  Ann C McKee; Daniel H Daneshvar; Victor E Alvarez; Thor D Stein
Journal:  Acta Neuropathol       Date:  2013-12-24       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.